Two studies could lead to new personalized therapies for lung cancer patients

September 13, 2012, Cell Press
A CIRCOS plot (Krzywinski 2007) maps genomic alterations observed through next generation sequencing of a set of lung adenocarcinoma patients to the 10 "hallmarks of cancer" (Hanahan and Weinberg, 2011). Each radial position in the plot represents a hallmarks and tumor combination, with position i in each hallmark corresponding to patient i. Tracks surrounding the hallmark labels signify mutation (colored boxes) and copy number status (line plot) for genes associated with that hallmark across the tumor set. For each predicted driver alteration in a gene and tumor, a colored set of arcs is drawn joining hallmarks predicted to be acquired in that tumor, with the identity of the tumor and gene signified by the position and color of the arc, respectively. Credit: Imielinski et al. in the journal Cell

Lung cancer is a leading cause of death worldwide and is associated with very low survival rates. Two new genome-sequencing studies have uncovered novel genes involved in the deadly disease, as well as striking differences in mutations found in patients with and without a history of smoking. The findings, published September 13th by Cell Press in the journal Cell, could pave the way for personalized therapies that boost survival rates.

"These efforts should spur more studies to fully understand the genomic landscape of lung cancer—more specifically, those who have no history of ," says study author Ramaswamy Govindan of Washington University School of Medicine. "This will help us to identify new targets for therapy to improve the outcomes of our ."

Lung cancer kills more than 1.3 million people each year, and the five-year survival rate is only about 16%. Although smoking is a major risk factor for the disease, a large percentage of these patients have no history of smoking. Past studies have suggested that different patients, including smokers and non-smokers, may have different sets of mutations that could affect how well they respond to drug treatments.

In one of the new studies, a team led by Richard Wilson of Washington University School of Medicine sequenced the genomes of tumors from patients with non-small cell lung cancer (NSCLC)—the most common type of lung cancer. They found that the was more than ten times higher in tumors from smokers than in those from non-smokers with NSCLC, and these two groups had different sets of mutations. Moreover, the researchers revealed mutations that could be responsible for triggering the disease and identified changes in 54 genes that could be targeted with existing drugs.

The second study, which was led by Matthew Meyerson of the Broad Institute and focused on a subtype of NSCLC called lung adenocarcinoma, also found different patterns of mutations in tumors from smokers compared with those from non-smokers and revealed mutations in genes never before implicated in cancer. "This is the largest genomic study of lung adenocarcinoma to date," says study author Alice Berger of the Broad Institute. "Our results are a testament to the power of large-scale next-generation sequencing technology to expand our understanding of tumor biology."

Explore further: Lung tumors in never-smokers show greater genomic instability than those in smokers

More information: Govindan et al.: "Genomic Landscape of Non-small Cell Lung Cancer in Smokers and Never Smokers." DOI:10.1016/j.cell.2012.08.024
Imielinski et al.: "Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing." DOI: 10.1016/j.cell.2012.08.029

Related Stories

Lung tumors in never-smokers show greater genomic instability than those in smokers

July 5, 2011
Lung adenocarcinomas in people who have never smoked show greater genome instability than those in smokers, supporting the theory that lung cancer in never smokers arises through different pathways, according to research ...

Researchers map potential genetic origins, pathways of lung cancer in nonsmokers

January 9, 2012
Researchers at the Translational Genomics Research Institute (TGen) have begun to identify mutations and cellular pathway changes that lead to lung cancer in never-smokers -- a first step in developing potential therapeutic ...

Gene fusion in lung cancer afflicting never-smokers may be target for therapy

December 22, 2011
Smoking is a well-known risk factor for lung cancer, but nearly 25% of all lung cancer patients have never smoked. In a study published online today in Genome Research, researchers have identified a previously unknown gene ...

Study finds increase in number of non-smokers being diagnosed with lung cancer

September 4, 2012
There has been an increase in the number of non-smokers being diagnosed with non-small cell lung cancer, according to new findings.

Latest research confirms genetic susceptibility to lung cancer

April 15, 2012
Previous research has shown that Asian patients with lung cancer are more likely to harbor epidermal growth factor receptor (EGFR) mutations. Furthermore, Asian patients with lung cancer are more likely to be non-smokers ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.